Shutter2U Investment Overview In the first of my two most recent pieces of coverage for Seeking Alpha on AstraZeneca PLC (NASDAQ:AZN), the Anglo / Swedish Pharma giant, I gave the company and its stock a “buy” recommendation in February. This was after a sell-off in response to a Q4 2023 earnings miss created a buying opportunity. Then, in late May, I gave it a “hold” recommendation, shortly after the company had revealed ambitious plans to exceed $80bn in top-line revenues by 2030. AstraZeneca stock is ...

AstraZeneca’s (AZN) stock has risen 18.4% so far this year, underperforming an increase of 23.4% for the industry, as seen in the chart below. AstraZeneca’s stock has, however, outperformed the sector as well as the S&P 500.AstraZeneca Stock Performance Image Source: Zacks Investment ResearchAstraZeneca boasts a diversified geographical footprint as well as product portfolio with several blockbuster medicines. AstraZeneca now has 12 blockbuster medicines in its portfolio with sales exceeding $1 billion, inc ...

LYON, France and CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, today announced that its previously announced acquisition by the global pharmaceutical company, AstraZeneca, has closed. The acquisition bolsters the Alexion, AstraZeneca Rare Disease late-stage pipeline and expands on its bone metabolism franchise with the notable addition of eneboparat ...

AstraZeneca (AZN) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its PD-L1 inhibitor Imfinzi (durvalumab) as a treatment for certain patients with primary advanced or recurrent endometrial cancer.The CHMP recommended the approval of Imfinzi plus chemotherapy, followed by Imfinzi and Lynparza as a first-line treatment for patients with mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer.The CHMP ...

One of the greatest forces in wealth-building is the power of compounding. That is why every portfolio needs some set-it-and-forget-it stocks. When you find a good compounder, you should hold it forever.It is well known that investors do poorly timing the market. Due to the psychological nature of investing, most investors tend to buy at the top and sell at the bottom. As a result, they end up underperforming the market indices.Similarly, trying to time the tops and bottoms in the best-in-class compounders ...

While innovations such as artificial intelligence have become all the rage, there’s another type of technology – biotechnology – that deserves careful consideration for your portfolio. Indeed, if you haven’t considered the sector, it’s really time to focus on biotech stocks.First, let’s get the obvious matter out of the way: biotech stocks benefit broadly from a permanently relevant narrative. That doesn’t mean individual companies are guaranteed to rise. It’s just that the concept of addressing diseases an ...

AstraZeneca (AZN) announced positive results from the phase III NIAGARA study, which evaluated Imfinzi in patients with muscle-invasive bladder cancer (MIBC).Study participants who were enrolled in the NIAGARA study were randomized to receive Imfinzi plus chemotherapy or chemotherapy alone before cystectomy (bladder removal surgery), followed by Imfinzi or no further treatment after surgery.The study achieved statistically significant and clinically meaningful improvement in its primary endpoint of event-fr ...

There are multiple reasons to consider exposure to pharmaceutical stocks for the long-term portfolio. First, pharma stocks have a low-beta and provide and help in reducing the overall beta of a portfolio that’s overweight growth stocks. Further, pharma stock represents a business that’s relatively immune to economic shocks.At the same time, well established pharma companies have healthy cash flows and therefore sustained value creation through dividends. With these factors in consideration, investors should ...

You won't need much money to start investing in these great stocks.A low price doesn't necessarily mean low quality. That's true with lots of products and services. And it's true with stocks, too.We asked Three Motley Fool contributors to name no-brainer healthcare stocks to buy for under $100 right now. Here's why they picked AstraZeneca (AZN 0.41%), Bristol Myers Squibb (BMY 2.17%), and Pfizer (PFE).AstraZeneca is a growth beast with loads of potential upsideDavid Jagielski (AstraZeneca): Shares of AstraZ ...

AstraZeneca (AZN) announced that the European Commission (EC) has approved Truqap (capivasertib) in combination with Faslodex (fulvestrant) for a breast cancer indication.The EC has approved Truqap in combination with Faslodex for treating adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer whose tumors have qualifying alterations in the PIK3CA, AKT1 or PTEN genes following recurrence or progression on or after an endocrine-based regimen.Following ...